Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 7/23/26 | Johnson & Johnson (JNJ) | Tecvayli for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | Takeda (4502) | Velcade for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/23/26 | Johnson & Johnson (JNJ) | Talvey for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/15/26 | Merck & Co (MRK) | Keytruda for Uterine (Endometrial) Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/15/26 | Roche (RO) | Gazyva for Membranous Nephropathy | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |